Stockscreener 앱 받기
26.94
3.02%
0.79
시간 외 거래:
26.94
전일 마감가:
$26.15
열려 있는:
$26.5
하루 거래량:
1.37M
Relative Volume:
0.84
시가총액:
$4.56B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
149.67
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
+0.90%
1개월 성능:
-1.82%
6개월 성능:
+28.59%
1년 성능:
+54.30%
1일 변동 폭
$26.36
$26.98
1주일 범위
$25.56
$26.98
52주 변동 폭
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
26.94 | 4.42B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
ACADIA Pharmaceuticals (ACAD) Sees Target Price Raised by Citigr - GuruFocus
UBS Raises Price Target to $40 for ACADIA Pharmaceuticals (ACAD) - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Hold" at Wall Street Zen - MarketBeat
What drives ACADIA Pharmaceuticals Inc stock priceMean Reversion Trades & Outstanding Wealth Building - earlytimes.in
ACADIA Pharmaceuticals Earnings Notes - Trefis
Insider Sell: Is ACADIA Pharmaceuticals Inc stock in correction or buying zoneIndex Update & Risk Controlled Swing Alerts - moha.gov.vn
(ACAD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Deutsche Bank Upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Performance Recap: Can ACADIA Pharmaceuticals Inc stock hit analyst price targetsWeekly Earnings Recap & Verified Swing Trading Watchlists - moha.gov.vn
Rice Hall James & Associates LLC Sells 54,869 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. $ACAD Holdings Decreased by Assenagon Asset Management S.A. - MarketBeat
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - AOL.com
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - sharewise.com
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's Why - MarketBeat
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 - Investing.com
Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho - MSN
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally - Yahoo Finance
Can ACADIA Pharmaceuticals Inc. stock maintain growth trajectoryWeekly Trading Summary & Reliable Breakout Stock Forecasts - Улправда
How ACADIA Pharmaceuticals Inc. stock compares to growth peers2025 EndofYear Setup & Weekly High Return Forecasts - ulpravda.ru
Market Recap: How ACADIA Pharmaceuticals Inc. stock compares to growth peersJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is ACADIA Pharmaceuticals Inc. stock a defensive play in 2025Portfolio Update Summary & Fast Momentum Stock Entry Tips - Улправда
Can ACADIA Pharmaceuticals Inc. stock hit analyst price targets2025 Major Catalysts & Precise Buy Zone Identification - DonanımHaber
Will ACADIA Pharmaceuticals Inc. stock see PE expansionWeekly Trend Report & High Conviction Trade Alerts - DonanımHaber
Can ACADIA Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Patterns & Real-Time Buy Signal Alerts - DonanımHaber
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - Yahoo Finance
Is ACADIA Pharmaceuticals Inc. stock a good choice for value investorsQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - Улправда
What is HC Wainwright's Forecast for ACAD FY2028 Earnings? - MarketBeat
FDA approves Acadia’s Daybue Stix for Rett syndrome - MSN
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel maintains ACADIA Pharmaceuticals (ACAD) hold recommendation - MSN
New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD) - simplywall.st
Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright - Investing.com
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Trimmed by Hudson Bay Capital Management LP - MarketBeat
Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome - Indian Pharma Post
ACAD Sees Boost in Price Target by HC Wainwright & Co. | ACAD St - GuruFocus
Neuren Pharmaceuticals’ partner Acadia gains FDA approval for new Rett syndrome treatment - MSN
FDA Approves Acadia Pharmaceuticals’ Daybue Stix for Treating Rett Syndrome - geneonline.com
FDA approves Acadia’s Daybue Stix for Rett syndrome treatment - Pharmaceutical Technology
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment - TipRanks
Hohimer Wealth Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
FDA approves powder formulation of trofinetide for Rett syndrome - Contemporary Pediatrics
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (t - GuruFocus
FDA Approves New Formulation for Acadia Pharmaceuticals' (ACAD) Rett Syndrome Treatment - GuruFocus
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):